PHARMACEUTICAL COMPOSITION, COMPRISING HUMAN HYALURONIDASE PH20 VARIANT AND DRUG, FOR SUBCUTANEOUS INJECTION

摘要

The present disclosure relates to a pharmaceutical composition including (a) a drug and (b) a human PH20 variant.;The human PH20 variant included in the pharmaceutical composition according to the present disclosure includes amino acid residue substitution (s) in one or more regions selected from an alpha-helix 8 region (S347 to C381) and a linker region (A333 to R346) between alpha-helix 7 and alpha-helix 8 in wild-type human PH20 having the amino acid sequence of SEQ ID NO: 1, wherein amino acid residue (s) located at the N-terminus or the C-terminus is(are) selectively cleaved. In addition, the pharmaceutical composition according to the present disclosure may further include a pharmaceutically acceptable additive, particularly a stabilizer.;The pharmaceutical composition according to the present disclosure can maximize the therapeutic effect of a drug used in combination therewith, due to the effect of human PH20 variants.